- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03425799
Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This will be a multicenter, randomized, double-blind, parallel group study comparing tranexamic acid (test) to placebo (control) for reduction of perioperative blood loss after complex spinal fusion surgery (defined as T2 to Pelvis/Sacrum and greater than 4 Functional Spinal Units (4 discs/motion segments=5 Vertebral segments)). In addition to test and control treatments, all patients undergoing spinal fusion surgery will receive anesthesia and standard of care for blood loss including colloid/crystalloid fluid replacement and packed red cells, if necessary, according to a common multi-institutional protocol. Anesthesia will keep the mean arterial pressure as low as safe for the patient during exposure of surgery (estimated at 60-80 MAP). Patients will be randomized to receive either 30 mg/kg tranexamic acid as a one hour infusion (3 mL/kg) loading dose prior to start of procedure and as an infusion at 3 mg/kg/h (0.3 mL/kg/h) of tranexamic acid throughout the surgery in the test group; or, a one hour infusion at 3 mL/kg of 0.9% saline prior to start of the procedure and an infusion of 0.9% saline at 0.3 mL/kg/h in the control group. The maximum total dose will be 50 mg/kg.
The active phase of the study will be until discharge postoperatively for efficacy measurements and at 6 weeks for safety follow-up. The randomization will be open only to the statistician generating the randomization sequence. All PI(s), study conduct and monitoring staff, as well as the subjects will be completely blinded to the treatments except in the case of emergency.
The study will be terminated if ≥5/12 or 10/36 patients enrolled in the study are diagnosed with treatment related serious adverse events.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
California
-
Long Beach, California, Estados Unidos, 90806
- Memorial Orthopaedic Surgery Group
-
Los Angeles, California, Estados Unidos, 90048
- Cedars-Sinai Medical Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush University Medical Center - Division of Spine Surgery
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Spine Care Orthopedics - NYU Lagone Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- All adult patients (Male or Female) over age eighteen (>18) electively undergoing complex spinal fusion surgery (defined as T2 to Pelvis/Sacrum and greater than 4 Functional Spinal Units (4 discs/motion segments=5 Vertebral segments).
- Female subjects of childbearing potential with a negative serum (beta human chorionic gonadotropin [HCG]) pregnancy test at screening and urine pregnancy test at each admission; who are not breastfeeding; do not plan to become pregnant during the course of the study; and agree to use an approved method of birth control, such as condoms, foams, jellies, diaphragm, intrauterine device, sexual abstinence for at least 3 months prior to study
- Able to provide written informed consent after risks and benefits of the study have been explained
- Able to communicate effectively with study personnel.
Exclusion Criteria:
- History or presence of any clinically significant (based on the Investigator's judgment) cardiovascular, respiratory, metabolic, hepatic, gastrointestinal, renal, hematological, dermatological, neurological, or psychiatric disease or condition preventing the use of tranexamic acid
- History of renal failure or elevated creatinine above 1.4
- Any diagnosis of spinal tumor or intradural pathology
- Diagnosis of ankylosing spondylitis
- History or presence of acquired disturbance of color vision
- History of seizures
- History of thromboembolic event (DVT or PE) within the past year
- Current use of anticoagulant medications or past medical history leading to an abnormal coagulation profile preoperatively
- Subjects diagnosed with fibrinolytic disorders requiring intra-operative antifibrinolytic treatment; hematological disease (thromboembolic events, hemoglobinopathy, coagulopathy, or hemolytic disease)
- Significant drug sensitivity or significant allergic reaction to any drug, including tranexamic acid, based on the Investigator's judgment
- A subject who has donated or lost 450 mL or more blood volume (including plasmaphoresis) or had a transfusion of any product within 3 months prior to the initial study drug administration
- Pre-operative anemia (hb <110 in females, Hb <120 in males)
- Any subject that chooses to refuse blood products for ethical or religious purposes (Jehovah's Witness)
- Current participation in a drug or other investigational research study or participation within 30 days prior to the initial study drug administration
- A subject who may not be able to comply with the safety monitoring requirements of this clinical trial or is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
- Intraoperative cardiovascular, pulmonary, orthopedic, or anesthetic complication such as myocardial infarction, intraoperative fracture, vasopressor support or emergent intubation.
- Female patients who are using combination hormonal contraception.
- Patients with history of subarachnoid hemorrhage.
- Patients with serum creatinine above upper limit of normal (ULN).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador de Placebo: Sodium Chloride 0.9%
Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
|
Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Outros nomes:
|
Experimental: Tranexamic Acid 10 mg/mL
Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
|
Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Total Blood Loss
Prazo: From time of surgery until discharge
|
The Total Blood Loss will be estimated based on the hemoglobin content of the blood prior to surgery (mg/dL) and at each of the desired post-surgery time-points (mg/dL).
Blood samples for hemoglobin measurement will be collected prior to start of procedure, at the end of the procedure, at 24 h, and every 24 h thereafter until discharge and removal two subfascial drains.
|
From time of surgery until discharge
|
Incidence of Autologous or Allogenic Blood Transfusion
Prazo: From time of surgery until discharge
|
Number of Units of autologous transfusion and allogenic transfusion
|
From time of surgery until discharge
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Total Measured Blood Loss
Prazo: From time of surgery up to 24 hours after surgery
|
Estimated as 3x cell saver
|
From time of surgery up to 24 hours after surgery
|
Number of Patients With Symptomatic Anemia Precipitated Transfusion
Prazo: Until discharge
|
Number of patients with symptomatic anemia precipitated transfusion in each group
|
Until discharge
|
Number of Patients With Adverse Events Related to Tranexamic Acid
Prazo: up to 6 weeks
|
Number of patients with adverse events related to tranexamic acid in each group
|
up to 6 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Neel Anand, MD, Cedars-Sinai Medical Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CP-006-2017
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Fusão espinhal
-
Universitaire Ziekenhuizen KU LeuvenConcluídoRemoção da haste Wichita Fusion após artrodese do joelhoBélgica
-
Northwestern UniversityNational Institutes of Health (NIH); Northwestern Medical GroupRetiradoDor aguda | Bunionectomia | Toe FusionEstados Unidos
-
Memorial Sloan Kettering Cancer CenterUniversity of Pisa; University of California, San Francisco; The Champalimaud...Ativo, não recrutandoMelanoma | Sarcoma | Cancro do ovário | Osso | Tecido macio | Linfonodos | CNS-Spinal CD/MEMBR, NOSEstados Unidos, Itália, Portugal
-
St. Jude Children's Research HospitalNovartis PharmaceuticalsAtivo, não recrutandoGlioma | Neoplasias | Glioblastoma | Neoplasias Neuroepiteliais | Neoplasias do Sistema Nervoso Central | Cancer cerebral | Tumor cerebral | Ependimoma | Meduloblastoma | Astrocitoma Anaplásico | Ganglioglioma anaplásico | Ependimoma Anaplásico | Oligodendroglioma anaplásico | Pineoblastoma | Meduloblastoma recorrente | Tumor... e outras condiçõesEstados Unidos
Ensaios clínicos em Sodium Chloride 0.9% Inj
-
University of Colorado, DenverUniversity of Michigan; Brigham and Women's Hospital; Boston Medical CenterRecrutamento
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecrutamentoComplicações do Diabetes | Diabetes tipo 1 | Doença Renal Diabética | Nefropatias Diabéticas | Diabetes AutoimuneEstados Unidos